MK2206, a selective AKT inhibitor, modulates ovarian cancer cell line sensitivity to carboplatin plus paclitaxel

被引：0
|
作者：
Zgheib, N. Bou [1 ]
Marchion, D. [1 ]
Xiong, Y. [1 ]
Stickles, X. [1 ]
Judson, P. [1 ]
Hakam, A. [1 ]
Bosquet, J. Gonzalez [1 ]
Wenham, R. [1 ]
Apte, S. [1 ]
Lancaster, J. [1 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
342
引用
收藏
页码：S140 / S140
页数：1
相关论文
共 50 条
  • [21] Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma
    Rebecca, Vito W.
    Massaro, Renato R.
    Fedorenko, Inna V.
    Sondak, Vernon K.
    Anderson, Alexander R. A.
    Kim, Eunjung
    Amaravadi, Ravi K.
    Maria-Engler, Silvya S.
    Messina, Jane L.
    Gibney, Geoffrey T.
    Kudchadkar, Ragini R.
    Smalley, Keiran S. M.
    PIGMENT CELL & MELANOMA RESEARCH, 2014, 27 (03) : 465 - 478
  • [22] First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade
    Yap, Timothy A.
    Papadopoulos, Kyriakos
    Fearen, Ivy
    Carpenter, Christopher
    Delgado, Liliana
    Taylor, Adekemi
    Olmos, David
    Brunetto, Andre
    Tall, Matthew
    Decordova, Shaun
    Walton, Mike I.
    Heaton, Simon P.
    Garrett, Michelle D.
    Domsch, Julia
    Patnaik, Amita
    Sullivan, Daniel
    Yan, Li
    de Bono, Johann S.
    Tolcher, Anthony W.
    CANCER RESEARCH, 2010, 70
  • [23] Combination paclitaxel plus Carboplatin versus paclitaxel with alternating Carboplatin and cisplatin as first line treatment for advanced ovarian cancer (AOC)
    Aravantinos, G
    Fountzilas, G
    Kosmides, P
    Stathopoulos, GP
    Pavlidis, N
    Dimopoulos, MA
    Bafaloukos, D
    Papakostas, P
    Papadimitriou, C
    Nikolaides, G
    Skarlos, DV
    ANNALS OF ONCOLOGY, 1998, 9 : 66 - 66
  • [24] Akt inhibitor MK-2206 reduces pancreatic cancer cell viability and increases the efficacy of gemcitabine
    Wang, Zhanshan
    Luo, Guangtao
    Qiu, Zhengjun
    ONCOLOGY LETTERS, 2020, 19 (03) : 1999 - 2004
  • [25] The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway
    Liu, Ruixin
    Liu, Dingxie
    Trink, Eliana
    Bojdani, Ermal
    Ning, Guang
    Xing, Mingzhao
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04): : E577 - E585
  • [26] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models (vol 40, pg 1545, 2018)
    Lubet, Ronald A.
    Steele, Vernon E.
    Juliana, M. M.
    Bode, Ann
    Moeinpour, Fariba
    Grubbs, Clinton J.
    ONCOLOGY REPORTS, 2019, 41 (01) : 718 - 718
  • [27] Paclitaxel (Taxol(R)) plus carboplatin as first-line treatment for advanced ovarian cancer
    Ozols, RF
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 : 9 - 12
  • [28] Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer
    duBois, A
    Luck, HJ
    Meier, W
    Mobus, V
    Costa, S
    Richter, B
    Bauknecht, T
    Warm, M
    Schroeder, W
    Olbricht, S
    Nitz, U
    Jackisch, C
    SEMINARS IN ONCOLOGY, 1997, 24 (04) : 28 - 33
  • [29] First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care?
    du Bois, A
    Neijt, JP
    Thigpen, JT
    ANNALS OF ONCOLOGY, 1999, 10 : 35 - 41
  • [30] Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis
    Ding, Wei
    Shanafelt, Tait D.
    Lesnick, Connie E.
    Erlichman, Charles
    Leis, Jose F.
    Secreto, Charla
    Sassoon, Traci R.
    Call, Timothy G.
    Bowen, Deborah A.
    Conte, Michael
    Kumar, Shaji
    Kay, Neil E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (01) : 146 - 150
12345